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Sodium Channel Gene Mutations in Children with GEFS+ and Dravet
Syndrome: A Cross Sectional Study
Abstract
Objective
Dravet syndrome or severe myoclonic epilepsy of infancy (SMEI) is a 
baleful epileptic encephalopathy that begins in the first year of life. This 
syndrome specified by febrile seizures followed by intractable epilepsy, 
disturbed psychomotor development, and ataxia. Clinical similarities 
between Dravet syndrome and generalized epilepsy with febrile seizure plus 
(GEFS+) includes occurrence of febrile seizures and joint molecular genetic 
etiology. Shared features of these two diseases support the idea that these 
two disorders represent a severity spectrum of the same illness. Nowadays, 
more than 60 heterozygous pattern SCN1A mutations, which many are de 
novo mutations, have been detected in Dravet syndrome.
Materials & Methods
From May 2008 to August 2012, 35 patients who referred to Pediatric 
Neurology Clinic of Mofid Children Hospital in Tehran were enrolled in 
this study. Entrance criterion of this study was having equal or more than 
four criteria for Dravet syndrome. We compared clinical features and genetic 
findings of the patients diagnosed as Dravet syndrome or GEFS+.
Results
35 patients (15 girls and 20 boys) underwent genetic testing. Mean age 
of them was 7.7 years (a range of 13 months to 15 years). Three criteria 
that were best evident in SCN1A mutation positive patients are as follows: 
“Normal development before the onset of seizures, onset of seizure before 
age of one year, and psychomotor retardation after onset of seizures.
Our genetic testing showed that 1 of 3 (33.3%) patients with clinical Dravet 
syndrome and 3 of 20 (15%) patients that diagnosed as GEFS+, had SCN1A 
mutation.
Conclusion
In this study, normal development before seizure onset, seizures beginning 
before age of one year and psychomotor retardation after age of two years 
are the most significant criteria in SCN1A mutation positive patients.
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Introduction
Charlotte Dravet was the first scientist who described severs myoclonic epilepsy in 
infancy (SMEI) in 1978 at Marseille (1). The disorder has a prevalence of about
1/400,000 and is responsible for approximately 7% of severe epilepsies with seizure 
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greater than four characteristics of Dravet syndrome 
criteria obtained from Commission on Classification 
and Terminology of the International League Against 
Epilepsy (ILAE).
Any form of epilepsy with abnormal EEG findings and 
positive family history of febrile and nonfebrile
seizures with exacerbation of seizure with fever 
were the inclusion criterias for GEFS+ .Any form of 
epilepsy with abnormal EEG findings and positive 
family history of febrile and nonfebrile seizures with 
exacerbation of seizure with fever were the inclusion 
criterias for GEFS+.
All patients were aware of this study and informed 
consent was signed by parents before evaluations.
The primary evaluation included history taking, 
physical examination (general and neurologic), 
pedigree charting, electroencephalography (EEG), 
laboratory testing (biochemical and metabolic assay) 
and magnetic resonance imaging (MRI).
Three milliliters of whole blood was collected from the 
patients and their parents. Then, DNA was extracted 
from peripheral blood leukocytes using salting-out 
procedure described by miller et al. (9) and was qualified 
by Biophotometer, Eppendorf Spectrophotometer 
000576, Eppendorf Company, Hamburg, Germany. All 
coding regions of SCN1A were amplified using intronic 
primers and the products were sequenced directly by 
ABI Sequence Analyzer 3130.
All negative samples for sequence variations and 
point mutations were screened by multiplex ligation-
dependent probe amplification (MLPA) for detection 
of SCN1A deletions, Insertions or large gross 
rearrangements (10-12).
After genetic study, we have followed all the patients 
with known mutations according to their clinical 
course and evolutionary status until now. We analyzed 
clinical pictures and genetic features by Fisher’s exact 
test using SPSS software.
Results
Thirty five patients (15 girls and 20 boys) underwent 
genetic testing. Mean age of them was 7.7 years (a 
range of 13 months to 15 years). Four features of ILAE 
criteria that were more pronounced in these patients 
were as follows: 1- multiple seizure types (33 of 35, 
onset before age 3 years (2). Criteria for diagnosis of 
Dravet syndrome obtained from international league 
against epilepsy (ILAE) are as follows: 1- normal 
development before seizure, 2- seizure onset before 
one year of age, 3- multiple seizure type, 4-family 
history of epilepsy or febrile convulsion, 5- abnormal 
EEG findings, 6- psychomotor retardation after age 2 
years, 7- ataxia and pyramidal signs, 8- anticonvulsant 
resistance, and 9-exacerbation of seizure with fever (3).
GEFS+ or generalized epilepsy with febrile seizure 
plus is a familial epileptic syndrome inherited as an 
autosomal- dominant characteristic that even in a 
genotypically identical family has a great phenotypic 
heterogeneity pattern. The most prevalent clinical 
manifestation of GEFS+ is febrile seizure that may 
appear after the age range of classical febrile convulsion 
(3 months to 6 years) and can be accompanied by 
multiple types
(myoclonic, atonic or partial) of seizure (4,5).
Dravet syndrome and GEFS+ are two characteristics of 
one spectrum, while Dravet syndrome presents more 
severe clinical manifestations than GEFS+ (6). These 
two epilepsy syndromes are most commonly related 
to mutation in sodium channel gene famili subunits 
(SCN), including GEFS+ on the minor end and Dravet 
syndrome on the major end of the spectrum (7).
In patients clinically recognized as Dravet syndrome, 
mutations in SCN1A gene are detected in 33-100% 
of cases. The sodium channel α1-subunit encoding 
protein acts as a neuronal voltage-gated sodium 
channel α1-subunit encoding gene. Voltage-gated 
sodium channel α1-subunit is dominantly presented in 
the central nervous system (8). This study was designed 
to provide guidance for physicians, pediatrics, and 
pediatric neurologists to diagnose the patients with 
Dravet syndrome or GEFS+ and to provide appropriate 
indications for mutation analysis of the SCN1A gene. 
To this purpose, we compared clinical features of 
patients diagnosed as Dravet syndrome and GEFS+.
Materials & Methods
From May 2008 to August 2012, 35 patients who 
referred to Pediatric Neurology Clinic of Mofid 
Children Hospital in Tehran were enrolled in this study. 
Entrance criterion of this study was having equal or 
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94.2%), 2- positive family history of epilepsy or febrile 
seizure (30 of 35, 85%), 3- resistance to multiple 
anticonvulsants (27 of 35, 77.1%), 4- exacerbation of 
seizures with hyperthermia (27 of 35, 77.1%). Table one 
presents description of all patients on the basis of ILAE 
criteria. Based on clinical evaluations, these patients 
were classified into five categories as follows: atypical 
febrile convulsion (5.7%), generalized epilepsy febrile 
seizure plus (85.7%), and Dravet syndrome (8.6%).
After genetic study, SCN1A mutation was found in 
four patients, three belonging to GEFS+ spectrum and 
one from Dravet group.
The average age of seizure onset was 14.5 months (a 
range of 45 days to 4 years), while these four mutation 
positive patients manifested their first onset of seizure 
before age of one year (an average age of 8.4 months). 
All mutation positive patients and 38.7% of the 
mutation negatives had normal development before 
seizure onset. According to psychomotor retardation 
after 2 years of age, all of the mutation positives and 
37.1% of the others had these criteria.
Concerning these three characteristics (seizure onset 
before age 1 year, normal development before seizure 
onset, and psychomotor retardation after age 2 years), 
there were significant differences between mutation 
positive and mutation negative patients (p<0.05).
Our genetic testing showed that 1 of 3 (33.3%) patients 
with clinically Dravet syndrome and 3 of 20 (15%) 
patients diagnosed as GEFS+, had SCN1A mutation.
The further confirmed molecular genetic screening 
of child clinically categorized as Dravet showed a 
heterozygous missense in exon 2 as p.S103G, which 
causes a serine to glycine substitution in N-terminus 
of SCN1A gene and results in Dravet syndrome (13). 
Molecular analysis of the first patient with diagnosis 
of GEFS+ showed a novel unreported heterozygous 
sequence variation in codon 412, D1/S6 transmembrane 
domain of SCN1A protein, causing a phenylalanine 
to isoleucine substitution. Novel missense in codon 
1274 resulting in a tyrosine to asparagine substitution 
with heterozygous novel sequence variation occuring 
in exon19, D3/S2 transmembrane domain of SCN1A 
gene was detected in the second patient diagnosed 
as GEFS+. Molecular study of the third patient with 
features of GEFS+ revealed a missense as p.R101Z that 
Sodium Channel Gene Mutations in Children with GEFS+ and Dravet Syndrome: A Cross Sectional Study
resulted in arginine to glutamine substitution occurring 
in the N-terminus conserved domain of SCN1A gene 
(13).
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Table 1. Clinical Characteristics of Patients



























1 F 13m GEFS + + + - + - - + -
2 M 3.5y GEFS + - + + + - - + +
3 M 10 y GEFS + - - + + - - + -
4 F 10 y GEFS - - - - + + - + +
5 M 8 y GEFS - - - + + + - - +
6 M 8.5y GEFS + - - + + - - + +
7 F 6y GEFS + - - + + - - + +
8* M 15y GEFS + + - + + + - + +
9 F 9y GEFS + + + + + + - + +
10 F 4.5y GEFS - + - + + - - - +
11 M 10.5y GEFS - - - + + - - + +
12 M 9y Draret + + - - + + - + +
13 F 12y GEFS - - + + + - - + -
14 F 5y GEFS - + - + + - - + -
15 F 7y Dravet + + + + + + - + +
16 M 11y GEFS - + - + + - - - +
17* M 10y Dravet + + + + + + + + +
18 F 6y GEFS - - + + + - - + +
19 E 7.5y GEFS + + - + + - - - +
20 F 9y FC - + + + - - - - +
21 M 8 y FC - - + + + - - - +
22 E 5 y GEFS - + + + + + - - +
23 M 9y GEFS + + + + + + - + +
24* M 5.5y GEFS - - + + + + - + +
25 M 6y GEFS - - - + + - - + +
26 M 8y S.E - + - - + + - + -
27 F 10y GEFS - - - + + + - - +
28 M 9y GEFS + + - + + - - + +
29 M 15y GEFS + + - + + - - + +
30 M 6.5y GEFS - - + + + - - + -
31 M 8y GEFS - - - + + + - + +
32 M 7y GEFS + - - + + - - + +
33* F 9y GEFS + + + + + + + + +
34 F 9.5y GEFS - - + + + - - + -
35 M 13y GEFS - - + + + - - + -
GEFS+= generalized epilepsy with febrile seizure plus,*= SCN1A mutation positive patients
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Disussion
In this study, the three criteria that were best evident 
in SCN1A mutation positive patients were as follows: 
normal development before the onset of seizures, onset 
of seizure before age of one year, and psychomotor 
retardation after onset of seizures. These findings of 
the current study are consistent with those of Fountain-
Capal et al. who found three criteria, which best 
differentiated between mutation positive and mutation 
negative children. The three criteria comprised 
exacerbation with hyperthermia, normal development 
before seizure onset and ataxia, pyramidal signs or 
interictal myoclonus representation (14). Hattori et al. 
declared an age of febrile seizure onset less than or 
equal to 7 months, a total seizure number more than or 
equal to 5, and seizures lasting more than 10 minutes 
were the main risk factors for Dravet syndrome (15).
Another important finding was that mutations in 
SCN1A were evident in 33.3% of our patients clinically 
diagnosed as Dravet syndrome. This frequency is 
in agreement with Nabbout et al.’s findings which 
showed a frequency of 35% (16). The SCN1A mutation 
frequency in Fountain-Capal et al.’s studied patients was 
23% (16 of 69 children) that is lower than that of ours 
(14). 15% of patients who were clinically diagnosed 
as GEFS+ had SCANIA mutation. A Japanese groups 
detected mutation in SCN1A in 77-82% of patients 
with severe myoclonic epilepsy of infancy (Dravet) 
(17). However, approximately 35% of Dravet cases 
and 5-10% of GEFS+ cases had SCN1A mutation in 
Australian, French, Canadian, and Italian studies (18).
In our study, SCAN1A mutation was detected in 28.5% 
of children with febrile seizure onset before one years 
of age. In a study by Hattori et al., 6 of the 50 (12%) 
patients who had febrile seizure before their first year’s 
birthday, had SCN1A mutations (15).
Fujiwara et al. reported clinical features anticipating 
a worse developmental outcome in patients with 
Dravet syndrome included status epilepticus, 
interictal abnormalities within the first year of life, 
electroencephalography and motor disorder (19).
The average age of seizure onset in our mutation 
positive patients was 8.4 months and prior study by 
Dravet et al. and Engel. J. Jr et al. emphasized that the 
first seizure of these patients occurred at 5-8 months 
of age, while in a study of Fountain-Capal et al the 
seizure onset of 69 patients with Dravet syndrome 
was 2-16 months (14,20). In the two mutation positive 
patients, reported molecular genetic findings were able 
to corroborate clinical manifestations. Contrary to the 
previously published investigation, there
is some equivocation in penetrance and clinical 
presentation. This hesitancy raised by the third patient 
which diagnosed as GEFS+ as well. This patient was 
clinically diagnosed as GEFS+, while molecular study 
suggests a Dravet syndrome phenotype (21). These two 
novel heterozygous suite variations containing p.F412 I 
and p.Y1274N in D3/S2 domain diagnosed respectively 
in the first and second patients with GEFS+, may be 
more different from known mutations. In some studies, 
missense substitutions in D1/S6 domains in the first 
patient result in epileptic manifestations particularly 
Dravet syndrome, however, one study suggested 
that this domain mutation leaded to cryptogenic 
generalized epilepsy (22). Mutations reported in D3/
S2 domain detected in the second patient, usually cause 
both Dravet syndrome and GEFS+; however, clinical 
manifestations is more compatible with GEFS+ (23).
In conclusion, in this study, normal development 
before seizure onset, seizures beginning before age one 
year, and psychomotor retardation after age two years 
are the most significant criteria in SCN1A mutation 
positive patients.
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